Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. (Nasdaq: NXPS) is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for serious oncology conditions with unmet medical needs. The company operates through a single business segment dedicated to the research, development, and potential commercialization of targeted cancer therapeutics. The company website is www.nuvectis.com.

The company's primary product candidate is NXP900, a targeted-therapy small molecule drug that inhibits proto-oncogene c-Src and YES1 kinases, key members of the SRC kinase family. NXP900 represents a differentiated approach to SRC and YES1 inhibition, as it induces and locks these kinases in their inactive conformation, thereby inhibiting both catalytic and scaffolding functions rather than only enzymatic activity as with approved competitors. This mechanism is designed to provide an improved therapeutic window. The company licensed worldwide commercial rights to NXP900 from the University of Edinburgh in August 2021. In May 2023, the FDA cleared an IND application for NXP900 comprising a Phase 1a dose-escalation study and Phase 1b expansion study. The Phase 1a portion completed in July 2025, evaluating doses from 20 to 300 mg daily and demonstrating a robust pharmacodynamic response at higher doses with primarily mild to moderate gastrointestinal adverse events. The Phase 1b expansion initiated in August 2025 to evaluate NXP900 as both a single agent and in combination with EGFR and ALK inhibitors in specific tumor types.

The company also previously held rights to NXP800, a small molecule product candidate, but decided to cease clinical development following completion of a Phase 1b study in July 2025. Nuvectis employs 13 full-time employees and operates from its principal office in Fort Lee, New Jersey. The company has incurred losses since inception and has not generated any revenue, as it remains in the clinical development stage. The company's strategy focuses on advancing NXP900 through clinical development toward regulatory approval while leveraging business development expertise to potentially expand its product pipeline through licensing and acquisition opportunities.